Mizuho Reaffirms Buy Rating for Aerie Pharmaceuticals, Inc. (AERI)
“We expect an approval on or prior to the PDUFA date.”,” the firm’s analyst commented.
A number of other equities analysts have also recently issued reports on AERI. Canaccord Genuity reiterated a buy rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a research report on Monday, July 3rd. Stifel Nicolaus upped their price objective on shares of Aerie Pharmaceuticals from $55.00 to $65.00 and gave the stock a buy rating in a research report on Tuesday, July 4th. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 11th. Cantor Fitzgerald reiterated an overweight rating and set a $62.00 price objective (up from $56.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, July 20th. Finally, BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research report on Monday, July 24th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of Buy and an average price target of $68.92.
Shares of Aerie Pharmaceuticals (AERI) opened at 64.45 on Monday. The company’s market capitalization is $2.34 billion. The stock’s 50 day moving average is $56.24 and its 200 day moving average is $51.26. Aerie Pharmaceuticals has a 1-year low of $32.05 and a 1-year high of $66.10.
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.02. On average, equities research analysts anticipate that Aerie Pharmaceuticals will post ($2.59) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/19/mizuho-reaffirms-buy-rating-for-aerie-pharmaceuticals-inc-aeri.html.
Several large investors have recently bought and sold shares of AERI. BlackRock Inc. boosted its stake in shares of Aerie Pharmaceuticals by 113,376.8% in the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after purchasing an additional 2,598,596 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Aerie Pharmaceuticals by 55.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock valued at $113,446,000 after purchasing an additional 766,300 shares during the last quarter. Senzar Asset Management LLC bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter valued at $20,568,000. Broadfin Capital LLC bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter valued at $16,291,000. Finally, AXA bought a new stake in shares of Aerie Pharmaceuticals in the 2nd quarter valued at $10,961,000. 94.64% of the stock is currently owned by institutional investors.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.